Arbevel Life Sciences Crossover I fund

https://www.arbevel.com

Established in 1997, Financière Arbevel is an independent management company that has enjoyed solid growth since being taken over by Mr Lalevée and Mr Delabare in 2009. The company currently handles €1.8bn ($2bn) and employs 34 staff members, 13 of which are dedicated to management and research. Launched at the end of 2018, the Arbevel Life Sciences Crossover I fund is Financière Arbevel’s leading private equity vehicle. With €30M ($33M) at the first closing (the second closing is expected at the end of 2019), the fund has already provided four investments (NG Biotech, NH TherAguix, Keranova and TransCure bioServices). *

	Start	2018-12-31 established (approx)
	Group	Financière Arbevel
	Industry	private equity
	Industry 2	LIFE SCIENCES

	Region	France_oo
	Country	France
	Street	20 rue de la Baume
	City	75008 Paris
	Tel	+33-1-5659-1133
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2019-09-10)

		* Document for »About Section«: Keranova S.A.. (9/10/19). "Press Release: Keranova Raises €24m in Second Round of Financing". Saint-Etienne & Lyon.

		Record changed: 2024-02-12

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)